Friday, March 27, 2020 3:04:57 AM
TEVA to close week flat to lower.
Why? Total market closes three days higher and it's already winded, making it more likely that prices correct tomorrow. Also fairly likely as investors fear holding stocks over the weekend.
Preference: TEVA closes Friday slightly below $8 and as dragonfly doji as it produced on Tuesday. That signals that she's chomping at the bit and ready to run.
Seems plausible -- market too weak to go up another day, TEVA hooving the ground and anxious to run.
Hey, and I wouldn't have to waste time buying the stock back on Monday and probably pay too much for it.
Why? Total market closes three days higher and it's already winded, making it more likely that prices correct tomorrow. Also fairly likely as investors fear holding stocks over the weekend.
Preference: TEVA closes Friday slightly below $8 and as dragonfly doji as it produced on Tuesday. That signals that she's chomping at the bit and ready to run.
Seems plausible -- market too weak to go up another day, TEVA hooving the ground and anxious to run.
Hey, and I wouldn't have to waste time buying the stock back on Monday and probably pay too much for it.
Recent TEVA News
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • Business Wire • 02/20/2026 08:37:00 PM
- Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI • Business Wire • 02/20/2026 08:37:00 PM
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 02/20/2026 07:43:11 PM
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease • GlobeNewswire Inc. • 02/17/2026 11:00:00 AM
- Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/03/2026 01:58:40 PM
